Literature DB >> 11893040

Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru.

Carlos Barrionuevo1, Virginia M Anderson, Eduardo Zevallos-Giampietri, Mayer Zaharia, Oscar Misad, Francisco Bravo, Héctor Cáceres, Luis Taxa, Marco T Martínez, Antonio Wachtel, Miguel A Piris.   

Abstract

Hydroa-like cutaneous T-cell lymphoma (hydroa-like CTCL) is an unusual pediatric malignancy with a poor prognosis. An impressive cutaneous rash characterized by edema, blisters, ulcers, crusts, and scars, resembling hidroa vacciniforme, is seen mainly on the face and sometimes on the extremities. The lesion consists of lymphomatous T-cell infiltration of the skin and subcutis with variable exocytosis and angiocentricity. It has been also called edematous, scarring vasculitic panniculitis and hydroa-like lymphoma. An association with Epstein-Barr virus has been suggested. The differential diagnosis includes other cutaneous lymphomas, particularly the cutaneous nasal type T/natural killer-cell lymphoma, mycosis fungoides, precursor T-cell lymphoblastic lymphoma, nonspecific peripheral T-cell lymphoma, cutaneous anaplastic large cell lymphoma, and subcutaneous panniculitic T-cell lymphoma. Other differential diagnoses are inflammatory dermatopathies and panniculitides. Based on a series of 16 such cases referred to the Institute of Neoplastic Diseases, the objective of this report is not only to provide a better clinicopathologic understanding of this entity but also a reappraisal of it as a malignancy. The male/female frequency ratio was 1:1. The median age was 10 years old. All cases showed predominant facial involvement with edema, blisters, ulcers, crusts, and scars. Chemotherapy and/or radiotherapy had little or no benefit. The prognosis was usually dismal. The lymphoma extended from the epidermis to the subcutis, with frequent angiocentric and periadnexal array. Lymphoma cells were mostly of intermediate size with dense hyperchromatic nuclei, inconspicuous nucleoli, and infrequent mitosis. A scanty and variable inflammatory background was found. The lymphoma cells displayed T-cell cytotoxic phenotype. In addition, they were negative for the natural killer cell antigens CD56 and CD57. Epstein-Barr virus in situ hybridization was positive in the six cases in which it was assayed. T-cell receptor gamma (TCRgamma) displayed monoclonal-type rearrangement in four cases studied. Our findings indicate that hydroa-like CTCL is an independent clinicopathologic entity that affects children. Consequently, it should be considered an independent subset of CTCLs and be included as such in the classification of neoplastic diseases of the lymphoid tissues.

Entities:  

Mesh:

Year:  2002        PMID: 11893040     DOI: 10.1097/00129039-200203000-00002

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  18 in total

1.  Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma.

Authors:  Guan-Nan Wang; Yong Cui; Wu-Gan Zhao; Ling Li; Xu-Dong Zhang; Yu Chang; Xian-Zheng Gao; Ye Li; Ming-Zhi Zhang; Wen-Cai Li
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

2.  Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute.

Authors:  Rosana Ruiz; Zaida Morante; Raul Mantilla; Luis Mas; Luis Casanova; Henry L Gomez
Journal:  An Bras Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.896

Review 3.  Systemic lymphoma arising from hydroa vacciniforme-like lymphoma: report of two cases with review of literature.

Authors:  Yu-Qiong Yang; Lei Fan; Li Wang; Ji Xu; Run Zhang; Zheng Ge; Jian-Yong Li; Wei Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 4.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

5.  Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy.

Authors:  N K El-Mallawany; L Geller; C M Bollard; B Wistinghausen; F Mussai; A S Wayne; B Alobeid; M S Cairo
Journal:  Bone Marrow Transplant       Date:  2010-07-26       Impact factor: 5.483

Review 6.  Viral-associated lymphoid proliferations.

Authors:  Stefania Pittaluga
Journal:  Semin Diagn Pathol       Date:  2013-03-26       Impact factor: 3.464

7.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

Review 8.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

9.  Recurrent scarring papulovesicular lesions on sun-exposed skin in a 22-year-old man.

Authors:  Melissa A Levoska; Jeffrey I Cohen; Irini Manoli; Chyi-Chia Richard Lee; Steven S T Ching; Jessica Shand; Deborah Tamura; Kenneth H Kraemer; John J DiGiovanna
Journal:  J Am Acad Dermatol       Date:  2017-09-28       Impact factor: 11.527

10.  Hydroa Vacciniforme-Like Lymphoproliferative Disorder in Korea: Prognostic Implication of Clinical Signs and Whole Blood Epstein-Barr Virus DNA.

Authors:  Se Jin Oh; Jongeun Lee; Ji-Hye Park; Jong Hee Lee; Junhun Cho; Young-Hyeh Ko; Dongyoun Lee
Journal:  Ann Dermatol       Date:  2021-05-04       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.